Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncolytics Biotech announced that Chief Medical Officer Thomas Heineman will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 20, 2023. The event starts at 9:00 a.m. ET, and a live webcast will be accessible to registered attendees. Company management will also engage in virtual one-on-one investor meetings throughout the conference. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent designed to enhance anti-cancer immune responses for various cancers. The company is advancing clinical trials to evaluate pelareorep in combination with other treatments for conditions like metastatic breast and pancreatic cancer.
Details
News Market Reaction – ONCY
The recorded move for ONCY in the trading session of this news was -0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Date:
Time:
Panel Title: Viral Immunotherapy – Moving Forward
A live webcast of the panel presentation will be available to registered attendees of the conference through the conference website. Company management will also be participating in virtual one-on-one investor meetings at the conference. To schedule a meeting, contact your
About
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Company Contact Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics +1-917-679-9282 |
Logo - https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuitys-horizons-in-oncology-virtual-conference-301795462.html
SOURCE Oncolytics Biotech® Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.